Vladyslav Shapoval, Perrine Evrard, François-Xavier Sibille, María López-Toribio, Olivia Dalleur, Carole E. Aubert, Lucy Bolt, Vagioula Tsoutsi, Maria Ntafouli, Laura Fernández Maldonado, Ramon Miralles, Adam Wichniak, Katarzyna Gustavsson, Torgeir Bruun Wyller, Enrico Callegari, Jeremy M. Grimshaw, Justin Presseau, Séverine Henrard, Anne Spinewine
{"title":"Barriers to and Enablers of Supporting Deprescribing Benzodiazepines in Older Adults: A Survey of European Nonphysician Healthcare Professionals","authors":"Vladyslav Shapoval, Perrine Evrard, François-Xavier Sibille, María López-Toribio, Olivia Dalleur, Carole E. Aubert, Lucy Bolt, Vagioula Tsoutsi, Maria Ntafouli, Laura Fernández Maldonado, Ramon Miralles, Adam Wichniak, Katarzyna Gustavsson, Torgeir Bruun Wyller, Enrico Callegari, Jeremy M. Grimshaw, Justin Presseau, Séverine Henrard, Anne Spinewine","doi":"10.1111/bcpt.70100","DOIUrl":null,"url":null,"abstract":"<p>Although physicians are primarily responsible for Benzodiazepine Receptor Agonist (BZRA) deprescribing, nonphysician healthcare professionals (HCPs) can support deprescribing. This study explored barriers to and enablers of BZRA deprescribing among nonphysician HCPs. We surveyed 258 HCPs (63.2% nurses) working in hospital settings across six European countries using a questionnaire based on the Theoretical Domain Framework (TDF). Logistic regression assessed associations between TDF domains and both intentions to support and routine engagement in BZRA deprescribing. Major barriers (TDF items with mean < 3) were found in the goals (competing priorities), environmental context and resources (time and staff lack) and social influences (patient reluctance) domains. Five TDF domains were associated with a stronger intention to support deprescribing: social/professional role and identity (OR, 3.08; 95% CI, 1.77–5.46); beliefs about consequences (OR, 1.91; 95% CI, 1.07–3.34); memory, attention and decision processing (OR, 1.80; 95% CI, 1.16–2.82); intention to promote alternatives (OR, 1.63; 95% CI, 1.07–2.49); and reinforcement (OR, 1.57; 95% CI, 1.08–2.29). Knowledge was the only domain associated with routine BZRA deprescribing support (OR, 1.16; 95% CI, 1.06–1.27). Different categories of HCPs face similar major barriers, but barriers vary across HCP categories and countries. Context-specific, targeted interventions may enhance support for BZRA deprescribing.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"137 4","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.70100","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Basic & Clinical Pharmacology & Toxicology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/bcpt.70100","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Although physicians are primarily responsible for Benzodiazepine Receptor Agonist (BZRA) deprescribing, nonphysician healthcare professionals (HCPs) can support deprescribing. This study explored barriers to and enablers of BZRA deprescribing among nonphysician HCPs. We surveyed 258 HCPs (63.2% nurses) working in hospital settings across six European countries using a questionnaire based on the Theoretical Domain Framework (TDF). Logistic regression assessed associations between TDF domains and both intentions to support and routine engagement in BZRA deprescribing. Major barriers (TDF items with mean < 3) were found in the goals (competing priorities), environmental context and resources (time and staff lack) and social influences (patient reluctance) domains. Five TDF domains were associated with a stronger intention to support deprescribing: social/professional role and identity (OR, 3.08; 95% CI, 1.77–5.46); beliefs about consequences (OR, 1.91; 95% CI, 1.07–3.34); memory, attention and decision processing (OR, 1.80; 95% CI, 1.16–2.82); intention to promote alternatives (OR, 1.63; 95% CI, 1.07–2.49); and reinforcement (OR, 1.57; 95% CI, 1.08–2.29). Knowledge was the only domain associated with routine BZRA deprescribing support (OR, 1.16; 95% CI, 1.06–1.27). Different categories of HCPs face similar major barriers, but barriers vary across HCP categories and countries. Context-specific, targeted interventions may enhance support for BZRA deprescribing.
期刊介绍:
Basic & Clinical Pharmacology and Toxicology is an independent journal, publishing original scientific research in all fields of toxicology, basic and clinical pharmacology. This includes experimental animal pharmacology and toxicology and molecular (-genetic), biochemical and cellular pharmacology and toxicology. It also includes all aspects of clinical pharmacology: pharmacokinetics, pharmacodynamics, therapeutic drug monitoring, drug/drug interactions, pharmacogenetics/-genomics, pharmacoepidemiology, pharmacovigilance, pharmacoeconomics, randomized controlled clinical trials and rational pharmacotherapy. For all compounds used in the studies, the chemical constitution and composition should be known, also for natural compounds.